Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV

Frédérique Chammartin, Katharina Kusejko, Chloé Pasin, Alexandra Trkola, Matthias Briel, Patrizia Amico, Marcel P Stoekle, Anna L Eichenberger, Barbara Hasse, Dominique L Braun, Macé M Schuurmans, Thomas F Müller, Michael Tamm, Nicolas J Mueller, Andri Rauch, Michael T Koller, Huldrych F Günthard, Heiner C Bucher, Benjamin Speich, Irene A Abela, and the Swiss HIV Cohort Study, Frédérique Chammartin, Katharina Kusejko, Chloé Pasin, Alexandra Trkola, Matthias Briel, Patrizia Amico, Marcel P Stoekle, Anna L Eichenberger, Barbara Hasse, Dominique L Braun, Macé M Schuurmans, Thomas F Müller, Michael Tamm, Nicolas J Mueller, Andri Rauch, Michael T Koller, Huldrych F Günthard, Heiner C Bucher, Benjamin Speich, Irene A Abela, and the Swiss HIV Cohort Study

Abstract

We identified determinants of SARS-CoV-2 mRNA vaccine antibody response in people with HIV (PWH). Antibody response was higher among PWH less than 60 years, with CD4+ cell count superior to 350 cells/μl and vaccinated with mRNA-1273 by Moderna compared with BNT162b2 by Pfizer-BioNTech. Preinfection with SARS-CoV-2 boosted the antibody response and smokers had an overall lower antibody response. Elderly PWH and those with low CD4+ cell count should be prioritized for booster vaccinations.

Trial registration: ClinicalTrials.gov NCT04805125.

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

References

    1. Scherrer AU, Traytel A, Braun DL, Calmy A, Battegay M, Cavassini M, et al. Cohort profile update: the swiss HIV Cohort Study (SHCS) . Int J Epidemiol 2021; 51:33j–34j.
    1. Speich B, Chammartin F, Smith D, Stoeckle MP, Amico P, Eichenberger AL, et al. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna® . Trials 2021; 22:1–16.
    1. Speich B, Chammartin F, Abela IA, Amico P, Stoeckle MP, Eichenberger A. Antibody response in immunocompromised patients after the administration of SARS-CoV-2 vaccine BNT162b2 or mRNA-1273: a randomised controlled trial . Clin Infect Dis 2022; [in press].
    1. Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E, Cho A, et al. Plasma neutralization of the SARS-CoV-2 omicron variant . N Engl J Med 2022; 386:559–601.
    1. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, AlMukdad S, Yassine HM, Al-Khatib HA, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar . New Engl J Med 2022; 1–13. [in press].
    1. Ariën KK, Haque AA, Vandierendonck A, Weidensee B, Plovyt M, Stuchlíková M, et al. Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant . npj Vaccines 2022; 7:1–3.
    1. Abela IA, Pasin C, Schwarzmüller M, Epp S, Sickmann ME, Schanz MM, et al. Multifactorial seroprofiling dissects the contribution of preexisting human coronaviruses responses to SARS-CoV-2 immunity . Nat Commun 2021; 12:1–18.
    1. Anderson M, Stec M, Rewane A, Landay A, Cloherty G, Moy J. SARS-CoV-2 antibody responses in infection-naive or previously infected individuals after 1 and 2 doses of the BNT162b2 vaccine . JAMA Netw Open 2021; 4:e2119741.
    1. Mahdi M, Mótyán JA, Szojka ZI, Golda M, Miczi M, Tőzsér J. Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease . Virol J 2020; 17:190.
    1. del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy . Ann Intern Med 2020; 173:536–541.
    1. Frater J, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial . Lancet HIV 2021; 8:Wits VIDA COVID team.
    1. Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1 . Clin Microbiol Infect 2021; 27:1851–1855.
    1. Woldemeskel BA, Karaba AH, Garliss CC, Beck EJ, Wang KH, Laeyendecker O, et al. The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV) . Clin Infect Dis 2022; 74:1268–1270.
    1. Ruddy JA, Boyarsky BJ, Bailey JR, Karaba AH, Garonzik-Wang JM, Segev DL, et al. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV . AIDS 2021; 35:2399–2401.
    1. Noe S, Jonsson-Oldenbuettel C, Jaeger H, Schoenitzer V, Balogh A, Wolf E, et al. Humoral response to SARS-CoV-2 vaccines in people living with HIV . Infection 2021; [Epub ahead of print].
    1. Xu X, Vesterbacka J, Aleman S, Nowak P. High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters? . AIDS 2022; 36:479–481.
    1. Brumme ZL, Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Duncan MC, et al. Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy . NPJ Vaccines 2022; 7:
    1. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273 . JAMA 2021; 326:1533–1535.
    1. Stumpf J, Siepmann T, Lindner T, Karger C, Schwöbel J, Anders L, et al. Europe Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine . Lancet Reg Heal Eur 2021; 9:100178.
    1. Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB. Cytomegalovirus (CMV) seropositivity decreases B cell responses to the influenza vaccine . Vaccine 2015; 33:1433–1439.
    1. Kugler DG, Flomerfelt FA, Costa DL, Laky K, Kamenyeva O, Mittelstadt PR, et al. Systemic toxoplasma infection triggers a long-term defect in the generation and function of naive T lymphocytes . J Exp Med 2014; 213:3041–3056.
    1. Ferrara P, Gianfredi V, Tomaselli V. The effect of smoking on humoral response to COVID-19 vaccines: a systematic review of epidemiological studies . Vaccines 2022; 10:303.
    1. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA covid-19 vaccine in solid-organ transplant recipients . N Engl J Med 2021; 385:661–662.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe